XBiotech (XBIT) Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases


Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.


XBiotech Inc. (NASDAQ: XBIT) announced today that the European Patent Office has granted XBiotech a patent (Patent Number EP2694107) that covers the use of bermekimab as a treatment for inflammatory skin diseases. The patent includes data from studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α) can reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab (an anti- IL-1α antibody), including ongoing studies in hidradenitis suppurativa and atopic dermatitis. XBiotech has also published clinical findings for the use of bermekimab for treatment of psoriasis and acne. The development of bermekimab for the treatment of inflammatory skin disorders is an important part of XBiotech’s commercialization programs.

Stanley Kim, Ph.D., J.D., XBiotech’s Corporate Vice President of Intellectual Property, stated, “I am pleased that the European Patent Office acknowledged the significance of XBiotech’s contribution to this field by granting this patent with broad claims. As a pioneer in IL-1α research, XBiotech has developed a significant worldwide patent portfolio for the use of bermekimab to prevent and treat inflammatory skin diseases as well as other conditions involving sterile inflammation.”

This patent issuance further broadens XBiotech’s patent portfolio as it relates to bermekimab and its potential to treat inflammatory skin disorders through IL-1α blockade. XBiotech previously conducted clinical studies with bermekimab to treat dermatological conditions including psoriasis1, acne2 and hidradenitis suppurativa3. The Company is currently conducting two separate open label, phase 2, multi-center studies evaluating a subcutaneous formulation of bermekimab in pre-filled syringes for treatment of atopic dermatitis and hidradenitis suppurativa.

The grant of this patent in Europe is in addition to patents granted in the US, Australia, and Japan. The Company’s patent portfolio also includes several pending U.S. and foreign applications directed to dermatologic pathologies. The Company plans to continue to pursue inflammatory skin disorder indications as it further strengthens its clinical pipeline.

About 85 million Americans sought treatment from a physician for skin disease in 2013, with an estimated direct health care cost of $75 billion4. The economic impact and prevalence of skin disease is on a similar magnitude as other major diseases affecting the US population, including diabetes and cardiovascular disease. Consequently, revenues from new biological drugs used to treat skin diseases are growing rapidly. XBiotech believes bermekimab may emerge as a major new therapy for skin disease.

Dr. Kim has been XBiotech’s chief intellectual property counsel for over 10 years. Prior to joining XBiotech, Dr. Kim led his law firm’s patent and life sciences practices. Dr. Kim is a registered patent attorney, experienced in procuring domestic and foreign patents, licensing and joint ventures, intellectual property opinions and due diligence, strategic patent portfolio development, and intellectual property litigation matters. Dr. Kim holds a bachelor’s degree in Biology from Bowdoin College, a Ph.D. in Microbiology and Immunology from the University of Miami, and a law degree from Suffolk University.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *